Wednesday, August 18, 2021

SYNGENE | Stock Analysis & Price Outlook | Potential Outperformer

     

investment , finvestonline.com

Syngene International Ltd

CMP 629


➽  Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS).


➽ Key Stat

The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers.

It has 360+ active customers with engagements with 8 out of the top 10 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 4200+ scientists.

Income - 76% from US, 12% from Europe, 5% from Japan, 4% from India.


TCS | Stock Analysis & Price Outlook




Financial Data Highlights

Market Cap24997.62
Book Value/ Share70.974
Enterprise Value20954.56
Revenue TTM2357.20
Gross Profit TTM1527.70
Revenue /Share TTM58.89


Key Profit & Loss Data

Period31_Mar_2021Growth
Net Inc404.901.75 %
Ops Income380.201.04 %
Revenue2184.308.57 %
Ops Expense1804.1020.64 %
PBT469.209.23 %
Gross Profit1657.8014.59 %
Div Paid0100.00 %



 Technical & Price Levels

syngene share live price chart , finvestonline.com

Long position can be made for  the potential upside level of 674 in short term and 734 in mid term.



Thanks for your Precious Time.


Finvest Online
Telegram  :  https://t.me/finvestonlineChat






Disclaimer- The information on this blog are based on my personal opinion and experience, it should not be considered professional financial investment advice and in no way it should be considered as a tip. We does not take any compensation of any kind whatsoever from any reader,user and company that are mention on this website.  Please remember that this is a blog, and you do not need to agree with anything I write.We are not SEBI registered financial advisor or analyst.


No comments:

Post a Comment